Managing Side Effects of New Treatments for Small Cell Lung Cancer

Welcome back to the Oncology Brothers podcast! In this episode, we continue the three-part CME series on small cell lung cancer, focusing on adverse events and management strategies for extensive stage small cell lung cancer treatments. We are thrilled to have Dr. Misty Shields from the Indiana University join us to discuss the latest advancements in treatment options following the exciting data presented at ASCO 2025. We dived into the treatment algorithm for patients with good performance status, including the use of chemoimmunotherapy, lurbinectedin, and tarlatamab. Key topics covered in this episode: Overview of the current treatment landscape and new data from ASCO 2025 ⁠Common side effects associated with lurbinectedin and immunotherapy Strategies for managing adverse events, including hematologic toxicities and liver function monitoring ⁠The role of supportive care and palliative care in enhancing patient quality of life ⁠Collaboration between community oncologists and academic centers for optimal patient care Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/    Join us as we explore the challenges and opportunities in managing extensive stage small cell lung cancer, and learn how to provide the best care for patients facing this devastating disease. Accreditation/Credit Designation Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/practical-considerations-and-future-directions-for-new-treatment-strategies-in-sclc    #SCLCtoxicity #Lurbinectedin #Tarlatamab #SupportiveOncology #CMEoncology